Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue.

Therapeutic innovations in endocrine diseases - Part 4 : Pasireotide: Long-acting release somatostatin analogue.
Presse Med. 2016 May 27;
Authors: Wémeau JL
Abstract
Pasireotide, the latest long-acting release somatostatin analogue, is distributed more widely to the various somatostatin receptors, which theoretically increases its strength and broadens its scope. Does this reflect genuine therapeutic progress? Or rather does its reduced specificity cause too many adverse reactions to make it a significant therapeutic achievement?
PMID: 27242210 [PubMed - as supplied by publisher]

Source: Presse Medicale - May 26, 2016 Category: Journals (General) Authors: Wémeau JL Tags: Presse Med Source Type: research